

## RESULTS OF ANNUAL GENERAL MEETING

**Melbourne, Australia – 21 November 2024:** Percheron Therapeutics Limited (ASX:PER or “the Company”) is pleased to advise the result’s of today’s Annual General Meeting of shareholders.

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act, the results of the Annual General Meeting are set out in the attached report and include a summary of the poll voting results by proxies on each resolution considered at the Annual General Meeting.

All resolutions to be voted on at the meeting were decided on a poll.

As more than 25% of the votes were cast against Resolution 1 on the adoption of the Remuneration Report, this constitutes a first strike for the purposes of the Corporations Act 2001 (Cth).

The Board thanks shareholder for their attendance and participation at the Annual General Meeting.

---

### About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company’s lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor. Avicursen is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in December CY2024. The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact [info@PercheronTx.com](mailto:info@PercheronTx.com).

*This announcement has been authorized for release to the Australian Securities Exchange by the Company Secretary.*

---

**Percheron Therapeutics Limited**  
**Annual General Meeting**  
**Thursday, 21 November 2024**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. To Adopt the Remuneration Report	Ordinary	247,132,922 62.85%	137,454,630 34.96%	8,634,901 2.20%	4,753,936	259,838,530 65.31%	138,045,642 34.69%	4,753,936	Carried	No
2. To re-elect Dr Ben Gil Price as a Director	Ordinary	293,409,798 74.24%	91,733,189 23.21%	10,091,565 2.55%	7,713,736	307,912,090 77.09%	91,504,181 22.91%	8,193,736	Carried	N/A
3. Approval for issue of Options to Dr James Garner	Ordinary	254,868,102 65.08%	130,168,267 33.24%	6,605,679 1.69%	9,931,240	265,438,238 66.90%	131,315,529 33.10%	9,481,240	Carried	N/A
4. Approval for issue of Options to Dr Ben Gil Price	Ordinary	266,569,889 66.83%	123,708,420 31.01%	8,615,679 2.16%	4,054,300	279,456,275 69.25%	124,099,432 30.75%	4,054,300	Carried	N/A
5. Appointment of Auditor	Ordinary	342,271,070 88.71%	35,543,011 9.21%	8,017,501 2.08%	17,116,706	354,950,290 90.90%	35,543,011 9.10%	17,116,706	Carried	N/A
6. Approval of 10% Placement Capacity - WITHDRAWN	Special	WITHDRAWN								
7. Amendments to Constitution - WITHDRAWN	Special	WITHDRAWN								
8. Ratification of Prior Issue of Shares	Ordinary	159,869,172 60.42%	97,036,097 36.67%	7,703,309 2.91%	28,329,642	170,172,645 63.45%	98,031,552 36.55%	28,709,642	Carried	N/A
9. Approval of the issue of Adviser Options to Canaccord	Ordinary	251,624,175 63.11%	139,793,086 35.06%	7,296,973 1.83%	1,513,976	261,789,505 64.89%	141,646,428 35.11%	1,453,996	Carried	N/A

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

For personal use only